Lutetium Prostate-specific Membrane Antigen 617 and Its Potential as a Treatment of Prostate Cancer

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Review highlights effectiveness and safety of Lu PSMA-617 in metastatic prostate cancer, suggesting its potential role in therapy.

Lu PSMA-617 demonstrated notable increases in survival rates in patients with metastatic castration-resistant prostate cancer.
Clinical trials showed Lu PSMA-617's effectiveness even in refractory cases, with positive prostate-specific antigen response rates.
The mechanism involves targeted delivery of beta-emitting lutetium 177 to PSMA-expressing cancer cells, causing cell death.
Adverse effects of Lu PSMA-617 include hematological toxicity, xerostomia, and renal toxicity, requiring careful monitoring.

Agrawal et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark